| Name | Title | Contact Details |
|---|---|---|
Pete Dyke |
Chief People Officer | Profile |
Se-Se Yennes |
Senior Vice President, Corporate Strategy & New Product Planning | Profile |
Sherri Weiland |
Chief Human Resources Officer | Profile |
Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company`s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).
Solutions connectées pour le diagnostic médical
BioVectra Inc. is a Charlottetown, PE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Qosina is one of the leading medical device component suppliers of OEM components to medical and pharmaceutical industries. Explore our products today.
InSightec is the world leader and innovator of MR-guided Focused Ultrasound (MRgFUS). The company`s non-invasive therapy platforms, Exablate and Exablate Neuro, are proven technology based on sound clinical evidence for treating essential tremor, painful bone metastases and uterine fibroids. The company is dedicated to improving patient lives by collaborating with physicians, medical institutions, academic researchers and regulatory bodies around the world.